Eli Lilly completed the acquisition of Verve Therapeutics for $1.3bn.

Eli Lilly, a pharmaceutical company, completed the acquisition of Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, for $1.3bn. "This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment. We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease," Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development.